Psychedelic Medicine

Marking an impressive milestone in the development of MDMA-assisted psychotherapy for PTSD, the FDA has approved the treatment for Expanded Access, allowing certain patients access to the therapy before full market approval is granted.

A new study has described the discovery of a previously unknown cannabinoid. Dubbed THCP, the molecule is significantly more potent that its well-known counterpart THC, however, it is unknown how present it is in common cannabis strains.

New Atlas spoke to several leading psychedelic researchers to get their thoughts on three big future-forward questions. Where will psychedelic science be in 2030, what hurdles do researchers face, and what research topic is yet to be answered?

Results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing LSD. This Phase 1 trial is exploring whether microdosing could be useful as a therapeutic tool to treat Alzheimer’s disease.

Researchers are reporting positive results from an early trial exploring the safety profile of psilocybin doses in healthy adults. The trial also explored the potential of group dosing sessions as a way to speed up research and expand patient access.

Predicting a wave of psychedelic legalization over the coming decade, start-up Silo Wellness has developed a magic mushroom nasal spray focused on delivering controlled psychedelic microdoses. New Atlas spoke to CEO Mike Arnold to learn more.

An incredible new study has found a specifically timed infusion of ketamine can rewrite maladaptive reward memories. Subjects with harmful alcohol behaviors significantly reduced their drinking for nine months following a single ketamine treatment.

New research is presenting evidence that cannabis can significantly reduce the severity of headaches and migraines. But the question remains: why are scientists coming up with such discordant results on whether cannabis can reduce pain?

The US Food and Drug Administration (FDA) has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

An intriguing new study from Imperial College London is shedding light on how one of the world’s most powerful psychedelic substances alters brain activity, rapidly shifting a person’s brainwaves into a state that resembles dreaming.

A new study has for the first time revealed one of the molecular mechanisms by which CBD directly blocks the negative psychiatric side effects generated by THC.

Can a drug-induced psychedelic experience be replicated by virtual reality? Or, can VR induce its own unique altered state of consciousness?